Dermavant Reports P-III Study (ADORING 1) Results of Vtama (tapinarof) for Adults and Children with Atopic Dermatitis
- The P-III study (ADORING 1) evaluating Vtama (1%, qd) vs vehicle in a ratio (2:1) in 400 adults & pediatric patients aged down-2yrs. with mod. to sev. AD
- The results showed that 45.4% of patients achieved the 1EPs of a vIGA-AD of clear (0) or almost clear (1) with a 2-grade improvement from baseline @8wk., 55.8% achieved the 2EPs with ≥75% improvement in EASI, 55.8% of patients aged ≥12yrs. with a baseline PP-NRS score ≥4 achieved a ≥4-point reduction in the PP-NRS with significant improvement in itch (61.1%)
- No new safety or tolerability signals incl. children ≥2yrs. were reported, low study discontinuation rate due to AEs (1.9% vs 3.6%). The company is expected to file the sNDA of Vtama in Q1’24 for AD
Ref: Businesswire | Image: Dermavant
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.